US FDA Elevates Controlled Substances Coordinator To New Deputy CDER Director Role
Executive Summary
The move should increase the visibility of the FDA’s wide-ranging, and widely criticized, opioid epidemic response.
You may also be interested in...
US FDA Looking For Senior Leader In New Drugs Office To Oversee Substance Use Disorder Issues
The deputy Office of New Drugs director will have decision-making authority and help shape policy for substance use efforts.
US FDA Serves Notice: Approval Of OTC Naloxone Could Close Prescription Sales
Agency signals assurance about making naloxone available OTC, so much so that firms with approved NDAs for Rx products should prepare for an all-nonprescription market. After offering model label to spur OTC switch NDAs, FDA notice about OTC assessment is second unprecedented step on its naloxone journey since opioid crisis declared a public health emergency in 2017.
US FDA Serves Notice: Approval Of OTC Naloxone Could Close Prescription Sales
Agency signals assurance about making naloxone available OTC, so much so that firms with approved NDAs for Rx products should prepare for an all-nonprescription market. After offering model DFl to spur OTC switch NDAs, FDA notice about OTC assessment is second unprecedented step on its naloxone journey since opioid crisis declared a public health emergency in 2017.